Small conjugate-based theranostic agents: an encouraging approach for cancer therapy
Publication Type:Journal Article
Source:Chemical Society Reviews, Royal Society of Chemistry, Volume 44, Number 19, p.6670–6683 (2015)
The advances in genomics, proteomics, and bioinformatics have directed the development of new anticancer agents to reduce drug abuse and increase safe and specific drug treatment. Theranostics, combining therapy and diagnosis, is an appealing approach for chemotherapy in medicine which exhibits improved biodistribution, selective cancer targeting ability, reduced toxicity, masked drug efficacy, and minimum side effects. The role of diagnosis tools in theranostics is to collect the information of the diseased state before and after specific treatment. Magnetic particle-, mesoporous silica-, various carbon allotrope-, and polymer nanoparticle-based theranostic systems are well accepted and clinically significant. Currently, small conjugate-based systems have received much attention for cancer treatment and diagnosis. The structural architecture of these systems is relatively simple, compact, biocompatible, and unidirectional. In this tutorial review, we summarize the latest developments on small conjugate based theranostic agents for tumor treatment and diagnosis using fluorescence and magnetic resonance imaging (MRI). © The Royal Society of Chemistry 2015.
cited By 0
Cite this Research Publication
Related Research Publications
- An activatable theranostic for targeted cancer therapy and imaging
- Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia
- Advances in cancer nanomedicine
- Thermo-responsive fibrinogen nanogels: a viable thermo-responsive drug delivery agent for breast cancer therapy?
- Radio frequency responsive nano-biomaterials for cancer therapy